Multiantigenic subunitary vaccines against tuberculosis in clinical trials: Where do we stand and where do we need to go?

被引：4
作者：
Guapillo, Carolina [1 ]
Hernandez-Pando, Rogelio [1 ]
Alberto Flores-Valdez, Mario [2 ]
机构：
[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Patol, Secc Patol Expt, Mexico City, DF, Mexico
[2] Ctr Invest & Asistencia Tecnol & Diseno Estado Ja, Biotecnol Med & Farmaceut, Ave Normalistas 800, Guadalajara 44270, Jalisco, Mexico
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2016年 / 12卷 / 05期
关键词：
clinical trials; multiantigenic; tuberculosis; vaccines; MYCOBACTERIUM-TUBERCULOSIS; NEGATIVE ADULTS; IMMUNOGENICITY; MTB72F/AS02; ANTIGENS; HUMANS; SAFETY;
D O I：
10.1080/21645515.2015.1136760
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The idea of presenting this commentary is to bring attention to the current status of clinical tests from several multiantigen vaccine candidates based on proteins produced by means of genetic engineering and molecular biology approaches and to suggest how new emerging technologies (OMICs) and bioinformatics might benefit vaccine development for better control of tuberculosis.
引用
收藏
页码：1193 / 1195
页数：3
相关论文
共 50 条
[21]   Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 2: Where do we stand and where must we go next? [J].
Bartus, Raymond T. ;
Johnson, Eugene M., Jr. .
NEUROBIOLOGY OF DISEASE, 2017, 97 :169-178
[22]   Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go? [J].
Singh, Vaishali ;
Ulasov, Ilya ;
Gupta, Sachin ;
Singh, Anita ;
Roy, Vikas Kumar ;
Kharwar, Rajesh Kumar .
DISCOVERY MEDICINE, 2024, 36 (180) :22-47
[23]   Methodology of clinical trials with new molecular-targeted agents: where do we stand? [J].
Morabito, A. ;
Di Maio, M. ;
De Maio, E. ;
Normanno, N. ;
Perrone, F. .
ANNALS OF ONCOLOGY, 2006, 17 :VII128-VII131
[24]   Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going? [J].
Peng, Yan ;
Yan, Hongxiang ;
Mei, Wuxuan ;
Zhang, Pengfei ;
Zeng, Changchun .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (10) :1378-1391
[25]   Immunotherapy in Allergic Asthma: Where do We Stand? [J].
Cardona, Victoria .
ALLERGY, ASTHMA, COPD, IMMUNOPHYSIOLOGY & IMMUNOREHABILITOLOGY: INNOVATIVE TECHNOLOGIES, 2018, :25-32
[26]   Subcutaneous and sublingual immunotherapy:Where do we stand? [J].
Ayfer Yukselen ;
Seval Guneser Kendirli .
World Journal of Immunology, 2014, (03) :130-140
[27]   Current Melanoma Treatments: Where Do We Stand? [J].
Moreira, Alvaro ;
Heinzerling, Lucie ;
Bhardwaj, Nina ;
Friedlander, Philip .
CANCERS, 2021, 13 (02) :1-12
[28]   The issue of statin safety - Where do we stand? [J].
Grundy, SM .
CIRCULATION, 2005, 111 (23) :3016-3019
[29]   Dupuytren's disease: where do we stand? [J].
Grazina, Rita ;
Teixeira, Sergio ;
Ramos, Renato ;
Sousa, Henrique ;
Ferreira, Andreia ;
Lemos, Rui .
EFORT OPEN REVIEWS, 2019, 4 (02) :63-69
[30]   Sorafenib: Where Do We Go from Here? [J].
Siegel, Abby B. ;
Olsen, Sonja K. ;
Magun, Arthur ;
Brown, Robert S., Jr. .
HEPATOLOGY, 2010, 52 (01) :360-369
12345